Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. (2013)
Attributed to:
MRC Clinical Trials Unit as the London Hub for Trials Methodology Research
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1177/1740774512440342
PubMed Identifier: 22547421
Publication URI: http://europepmc.org/abstract/MED/22547421
Type: Journal Article/Review
Volume: 10
Parent Publication: Clinical trials (London, England)
Issue: 1 Suppl
ISSN: 1740-7745